All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

  TRANSLATE

The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Subgroup analysis of the ENDEAVOR trial: carfilzomib versus bortezomib for patients with multiple myeloma and renal impairment

Jan 14, 2019


In the open-label, multi-center phase III ENDEAVOR trial (NCT01568866) carfilzomib and dexamethasone (Kd56) showed superior progression-free survival (PFS) compared with bortezomib and dexamethasone (Vd) in patients with relapsed/refractory multiple myeloma (RRMM). It is important to evaluate the efficacy and safety of proteasome inhibitors in MM patients with renal impairment as renal failure is a common complication and can lead to dismal outcomes in this patient population. Our steering committee member, Professor Meletios Dimopoulos and colleagues conducted a subgroup analysis of ENDEAVOR to assess the safety and efficacy of Kd56 versus Vd in RRMM patients with varying degrees of renal impairment at randomization. The paper was published in Blood on 10 January 2019.

Data shown as Kd56 versus Vd cohorts

Patients and methods

  • N = 929 patients with RRMM from 27 countries
  • Patients were randomly assigned 1:1 to receive Kd56 or Vd
  • Previous treatment lines: one vs two vs three
  • ISS stage: 1 vs 2-3
  • Patients were divided into six groups according to creatinine clearance (CrCL)
    • CrCL ≥ 15 to < 50 mL/min: n = 85 (median age = 72 years) and n = 99 (median age = 72 years)
    • CrCL 50 to < 80 mL/min: n = 186 (median age = 68 years) and n = 177 (median age = 68 years)
    • CrCL ≥ 60 mL/min: n = 193 (median age = 60 years) and n = 189 (median age = 61 years)

Key findings

Efficacy

  • Median PFS
    • CrCL ≥ 15 to < 50 mL/min: 14.9 vs 6.5 months, HR = 0.49 (95% CI, 0.320–0.757)
    • CrCL 50 to < 80 mL/min: 18.6 vs 9.4 months, HR = 0.48 (95% CI, 0.351–0.652)
    • CrCL ≥ 60 mL/min: not reached (NR) vs 12.2 months, HR = 0.60 (95% CI, 0.434–0.827)
  • Median overall survival (OS)
    • CrCL ≥ 15 to < 50 mL/min: 42.1 vs 23.7 months, HR = 0.66 (95% CI, 0.443–0.989)
    • CrCL 50 to < 80 mL/min: 42.5 vs 32.8 months, HR = 0.83 (95% CI, 0.626–1.104)
    • CrCL ≥ 60 mL/min: NR vs 42.3 months, HR = 0.75 (95% CI, 0.554–1.009)
  • Complete renal response (CrCL improvement to ≥ 60 mL/min in any 2 consecutive visits if baseline CrCL < 50 mL/min) rates in patients with CrCL ≥ 15 to < 50 mL/min in the two treatment arms: 15.3% (95% CI, 8.4–24.7) vs 14.1% (95% CI, 8.0–22.6)
  • Median PFS and OS in complete renal responders
    • PFS: 14.1 vs 9.4 months, HR = 0.805 (95% CI, 0.438–1.481)
    • OS: 35.3 vs 29.7 months, HR = 0.91 (95% CI, 0.524–1.577)

Safety

Grade ≥ 3 adverse events

  • CrCL ≥ 15 to < 50 mL/min: 87.1% vs 79.4%
  • CrCL 50 to < 80 mL/min: 84.4% vs 71.8%
  • CrCL ≥ 60 mL/min: 77.1% vs 65.9%

Taken together, Kd56 improved PFS and OS in comparison with Vd in RRMM patients regardless of their baseline renal function. Furthermore, Kd56 showed a favourable safety profile that supports the use of Kd56 as standard of care for RRMM patients with renal impairment.

References

Your opinion matters

Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?